课题基金 / 基金详情

BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION

BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
双功能螯合剂在肿瘤定位中的应用
批准号:
6172225
负责人:
CLAUDE F. MEARES
金额:
$18.34万
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-06-01 至 2004-04-30

项目摘要

项目成果

CLAUDE F. MEARES的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The long-term goal of this project is to develop new ways in which chelated metal ions may be used in the detection and treatment of cancer. Bifunctional chelating agents are important to this work; these compounds contain a powerful metal-chelating group and may be attached covalently to biological molecules such as monoclonal antibodies or drugs such as bleomycin. The products form stable chelates with more than 50 chemical elements; these elements have many useful properties -- such as radioactivity, paramagnetism, luminescence, and catalytic activity -- which have current and future applications in medical diagnosis and treatment. Specific aims are to use newly prepared monoclonal anti-chelate antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an order of magnitude) in the presence of anti-chelate antibodies. The versatile chemistry of the new BLEDTA IV synthesis -- which links bleomycin to chelators and other groups via coordination to inert cobalt(III), with no covalent modification of bleomycin -- will be used to prepare tumor-localizing bleomycin analogs bearing side-chains which may have cytotoxic properties or act as photoaffinity labels for mechanistic studies. The use of chelate-tagged antitumor antibodies with metabolically cleavable linkages between antibody and chelate will be explored with the aim of improving tumor imaging by reducing background interference. New bifunctional chelators with macrocyclic structures will be prepared, aimed at preventing any loss of metal from chelate during metabolism and thus minimizing potential toxic side effects of certain procedures. The methodology involves chemical synthesis and purification, chemical modification of proteins (antibodies), trace metal chelation chemistry, and a large number of associated analytical procedures. The proposed studies should provide information relevant to a number of advanced technical methods, including nuclear medicine, radioimmunotherapy, nuclear magnetic resonance imaging, and immunoassay.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bispecific Antibody Engineering for AML RIT
Bispecific Antibody Engineering for AML RIT
Bispecific Antibody Engineering for AML RIT
Pretargeted Antibodies with Infinite Affinity
  • 批准号:
    6557062
  • 项目类别:
  • 资助金额:
    $24.07万
  • 财政年份:
    2003
  • 负责人:
    CLAUDE F. MEARES
  • 依托单位:
海外基金